
|Articles|February 15, 2004
QLT lowers verteporfin cost after CMS cuts reimbursement
Toronto-QLT Inc. is temporarily lowering the price of verteporfin (Visudyne, Novartis and QLT Inc.) by $55 after the Centers for Medicare & Medicaid Services (CMS) lowered the amount for which it would reimburse physicians.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement


















